• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Allurion Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    1/16/25 7:24:48 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email
    8-K
    false 0001964979 0001964979 2025-01-14 2025-01-14 0001964979 alur:CommonStockParValue0.0001PerShare2Member 2025-01-14 2025-01-14 0001964979 alur:WarrantsToPurchase0.056818SharesOfCommonStockFor202.50PerShare1Member 2025-01-14 2025-01-14

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 14, 2025

     

     

    ALLURION TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41767   92-2182207

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    11 Huron Drive

    Natick, MA, 01760

    (Address of Principal Executive Offices, including Zip Code)

    (508) 647-4000

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   ALUR   The New York Stock Exchange
    Warrants to purchase 0.056818 shares of Common Stock for $202.50 per share   ALUR WS   The New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01 Entry into a Material Definitive Agreement.

    On January 14, 2025, Allurion Technologies, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with funds affiliated with RTW Investments, LP (collectively, “RTW”), pursuant to which the Company agreed to sell to RTW 841,751 shares (the “Shares”) of its common stock, par value $0.0001 per share, for an aggregate purchase price of approximately $2.5 million at a purchase price per share of $2.97 (the “Private Placement”). The Private Placement closed on January 16, 2025 (the “Closing Date”).

    Pursuant to the Subscription Agreement, the Company has agreed to file a resale registration statement with the Securities and Exchange Commission (“SEC”) within 45 days after the Closing Date to register the resale of the Shares. The Company must use commercially reasonable efforts to have such registration statement declared effective by the SEC as soon as practicable, but in no event later than the date which shall be either (a) in the event that the SEC does not review such registration statement, 90 days after the Closing Date, or (b) in the event that the SEC reviews such registration statement, 120 days after the Closing Date (but in any event, no later than three business days following the SEC indicating that it has no further comments on the registration statement).

    This Current Report on Form 8-K is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. The offer, issuance and sale of the Shares issued or issuable pursuant to the Subscription Agreement have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws, and unless so registered, such securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.

    The foregoing description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by reference to the Subscription Agreement, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

    Item 2.02 Results of Operations and Financial Condition.

    On January 14, 2025, the Company issued a press release announcing the Private Placement and certain estimated preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 2.02, Item 9.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 3.02 Unregistered Sales of Equity Securities.

    Pursuant to the Private Placement described in Item 1.01 above, which description is incorporated by reference into this Item 3.02, the Shares were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) under the Securities Act and Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The sale of the Shares did not involve a public offering and was made without general solicitation or general advertising. RTW represented that it is an “accredited investor” as defined in Rule 501(a) of Regulation D under the Securities Act, and is acquiring the Shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Accordingly, the Shares have not been registered under the Securities Act or any state securities laws and such securities may not be offered or sold in the United States absent registration, or an exemption from registration, under the Securities Act and any applicable state securities laws.

    Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy Shares or any other securities of the Company.


    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    10.1    Subscription Agreement, dated as of January 14, 2025, between Allurion Technologies, Inc. and the investors named therein.
    99.1    Press Release issued January 14, 2025 furnished herewith.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

        ALLURION TECHNOLOGIES, INC.
    Date: January 16, 2025     By:  

    /s/ Brendan Gibbons

        Name:   Brendan Gibbons
        Title:   Chief Legal Officer
    Get the next $ALUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

    Company's recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process Allurion Technologies, Inc. (the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders' equity or (ii) at least $50 million in total mar

    3/2/26 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

    Allurion Technologies, Inc. (NYSE:ALUR) (the "Company" or "Allurion"), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the "January 2025 Warrants"), February 20, 2025 (the "February 2025 Warrants") and November 12, 2025 (the "November 2025 Warrants" and together with the January 2025 Warrants and the February 2025 Warrants, the "Existing Warrants"), at a reduced exercise price of $1.15 per share. The shares of common stock issuable upon exercise of the January 2025 Warra

    2/24/26 9:15:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Receives U.S. FDA Approval

    Approval provides Allurion with access to approximately 80 million Americans with obesity Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. "Today's approval is a watershed moment for Allurion and for obesity care in the United States," said Dr. Shantanu Gaur, Founder and Chief Executive Officer. "Our goal is to deliver patients metabolically healthy weight loss by helping them lose weight, keep it off, and maintain muscle. The Allurion Smart Capsule off

    2/23/26 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ALUR
    SEC Filings

    View All

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gibbons Brendan M. decreased direct ownership by 15% to 10,408 units (SEC Form 5)

    5 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    2/17/26 5:10:48 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Buch Ojas decreased direct ownership by 17% to 10,223 units (SEC Form 5)

    5 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    2/17/26 5:09:02 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Director Davin Michael R received a gift of 3,212 shares, sold $4,918 worth of shares (3,212 units at $1.53) and gifted 3,212 shares, decreasing direct ownership by 73% to 1,206 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    12/5/25 7:23:17 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Technologies downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

    11/14/24 8:29:33 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Allurion Technologies with a new price target

    TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    10/2/24 7:13:57 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    ROTH MKM initiated coverage on Allurion Technologies with a new price target

    ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    9/6/24 7:25:38 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    3/12/26 5:11:54 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Allurion Technologies Inc.

    SCHEDULE 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    3/2/26 4:20:17 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Allurion Technologies Inc.

    8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    3/2/26 9:18:49 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    View All

    Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

    Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

    9/3/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

    Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

    8/20/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

    Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

    6/5/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Financials

    Live finance-specific insights

    View All

    Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights Successfully passed U.S. Food and Drug Administration ("FDA") Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and no Form 483 issued Completed Premarket Approval ("PMA") Acceptance and Filing Reviews, entered Substantive Review for the Allurion Smart Capsule and successfully completed Day-100 meeting Entered into transaction to exchange all outstanding debt for convertible preferred equity and concurrently announced private placement fina

    11/12/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

    Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart Capsule Exchange of outstanding debt for shares of convertible preferred stock would result in Company being debt-free $5M private placement financing with participation from new and existing stockholders and a strategic partner with deep obesity expertise significantly strengthens Company's financial position as the Company seeks FDA approval Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced it has

    11/11/25 8:45:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

    Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 12, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay

    11/6/25 4:05:00 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:15:52 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

    SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    10/24/24 5:19:39 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care